Vesicourethral Anastomotic Stenosis (VUAS)
Reconstruction of the vesicourethral anastomosis after radical prostatectomy ± radiation. Incidence ~4.8% post-RP at median 3.4 months. Risk modifiers: adjuvant radiation, BMI, larger prostate, perioperative urine leak, transfusion, non-nerve-sparing technique; robotic prostatectomy and complete nerve-sparing are protective (Britton 2023). Single-procedure endoscopic success ~44%, but 91% of patients are ultimately managed successfully with repeat endoscopic procedures (mean 2.1 treatments; LaBossiere 2016) — unlike anterior urethral strictures, repeat endoscopic treatment for VUAS is justified. Holmium laser may be superior to other endoscopic modalities (LaBossiere 2016). The robotic platform offers comparable patency to open techniques with significantly lower de novo incontinence (16.6% vs 100% for perineal; Savun 2025).
Success rates should be interpreted cautiously — definitions of success vary (patent lumen, continence, freedom from reintervention), follow-up intervals differ, and most data come from small case series.
Decision Framework
| Clinical Scenario | First-Line | Second-Line (if first fails) | Recalcitrant / Refractory |
|---|---|---|---|
| First-time VUAS after RP (non-radiated) | Endoscopic incision (holmium laser preferred) or balloon dilation (drug-coated balloon a current first-line option; Berg 2025 HR 0.40 for recurrence) | Repeat endoscopic; endourethroplasty; TUITMR | Robotic reconstruction (primary re-anastomosis, Y-V plasty, or transvesical; ~75–91% patency) |
| First-time VUAS after RP + radiation | Endoscopic incision or drug-coated balloon dilation (expect shorter recurrence interval; Hacker 2022, Rozanski 2021) | Repeat endoscopic; endourethroplasty | Perineal dorsal onlay BMG urethroplasty (Sterling 2024; no de novo SUI, 86.6% satisfaction); robotic reconstruction |
| Recurrent VUAS (≥ 2 endoscopic failures) | Robotic transvesical reconstruction (RTV-BNR) (Lee / Eun 2025 — 91% patency, no de novo SUI) | Perineal D-BMG urethroplasty; endourethroplasty (Doležel 2024) | Continent catheterizable channel; urinary diversion |
| Obliterative VUAS (~47% of reconstruction candidates) | Robotic scar excision + mucosa-to-mucosa re-anastomosis ± transperineal urethral advancement (Rodriguez 2024); bladder flap | Open retropubic reanastomosis (~70–100% patency, ~10% de novo SUI; Pfalzgraf 2011) | Urinary diversion or continent catheterizable channel (Mitrofanoff) |
| VUAS + concurrent severe SUI | Achieve stable patent outlet first → tissue maturation 3–6 mo → delayed AUS or male sling | Robotic / retropubic reconstruction (avoid perineal — 83–100% de novo SUI) + delayed AUS | Urinary diversion |
| Devastated posterior urethra (multiple failed reconstructions) | Permanent suprapubic tube | Salvage prostatectomy + BN closure + cath stoma + augmentation (MD Anderson; 83% continence); urinary diversion ± simple cystectomy | Continent catheterizable channel (Mitrofanoff) |
Key BNC-vs-VUAS distinguishing principles. VUAS sits adjacent to the external sphincter, making continence preservation the dominant concern at every tier. Repeat endoscopic treatment is justified (91% cumulative success) — unlike anterior urethral strictures. Radiation history is the strongest modifier of treatment success, and the robotic platform has emerged as the preferred reconstructive approach when continence preservation matters. Dorsal onlay buccal mucosal graft (D-BMGU) is uniquely valuable in the post-prostatectomy + radiation subgroup because it avoids urethral transection.
Robotic VUAS Reconstruction Algorithm
Endoscopic evaluation of the stenosis caliber and external urinary sphincter (EUS) involvement drives operative choice (Naser-Tavakolian and Lee, "A Review of Management Options for Vesicourethral Anastomotic Stenosis and the Emergence of Robotic Reconstruction," Transl Androl Urol 2025;14(8):2405–2418, doi:10.21037/tau-24-503):
| Endoscopic finding | Operation |
|---|---|
| ≥ 10 Fr lumen, no EUS involvement | Non-transecting bladder flap — Y-V plasty or T-plasty |
| <10 Fr lumen, no EUS involvement | Excision and primary anastomosis; fall back to anterior bladder flap (Tanagho / robotic bladder flap) if fibrosis or length precludes tension-free anastomosis |
| Any caliber + extension past EUS | Urethral pull-through (combined robotic abdominal + perineal advancement) |
Treatment Database
| Technique | Tier | Success Rate | Best for / indication |
|---|---|---|---|
| Transurethral Incision (Holmium Laser / Cold Knife / DVIU) | Endoscopic — First-Line | ~44% (1×) / 91% (cumulative) | First-line VUAS after radical prostatectomy via any incision modality (holmium laser, cold knife/Collins, or DVIU). Repeat endoscopic treatment justified by 91% cumulative success. |
| Balloon Dilation | Endoscopic — First-Line | ~59% standalone | Adjunct to laser/cold-knife incision; standalone option in day-surgery models. |
| Transurethral Incision with Transverse Mucosal Realignment (TUITMR) | Endoscopic — Adjunct / Novel | 89% (1×) / 100% (2×) | Recurrent VUAS where mucosal coverage of the incision is desired without open reconstruction; useful in radiated patients. |
| Robotic Y-V Plasty | Reconstruction — Robotic | 75–90.5% patency | Recalcitrant VUAS after ≥2 endoscopic failures when bladder-flap advancement is feasible; counsel re: 83% de novo SUI risk. |
| Robotic Transvesical BN Reconstruction (RTV-BNR) | Reconstruction — Robotic | 91% at 22 mo | Recalcitrant VUAS with hostile space of Retzius (prior radiation/multiple operations); best continence preservation among reconstructive options. |
| Robotic Bladder Flap Posterior Urethroplasty | Reconstruction — Robotic | 78% (7/9) at 21 wk | Recalcitrant VUAS requiring excision of dystrophic tissue with VUA reconstructed from an anterior bladder-wall flap. |
| Robotic Subtrigonal BMG Inlay | Reconstruction — Robotic | Promising early data | Refractory VUAS where mucosal augmentation is preferred over excision/anastomosis. |
| Primary Re-Anastomosis (Open / Robotic) | Reconstruction — Open | 60–91% across approaches | Recalcitrant VUAS after failed endoscopic management; approach chosen based on radiation history, continence status, and tissue obliteration. |
| Tanagho Flap | Reconstruction — Open | — | Selective salvage for obliterative VUAS; female urethral reconstruction with total urethral loss. |
| Combined Abdominoperineal Approach (Transperineal Advancement / Pull-Through) | Reconstruction — Open | 83–96.5% (open) / 75–83% (combined robotic) | Long or obliterative defects requiring extensive distal urethral mobilization to reach the proximal stump; complex VUAS where insufficient healthy urethral length precludes a tension-free abdominal-only anastomosis. |
| Dorsal Onlay BMG (Sterling) — VUAS | Reconstruction — Graft-Based | 84% / 86.6% satisfaction | Post-prostatectomy + radiation VUAS where sphincter preservation is paramount; non-transecting alternative to Y-V plasty. |
| Endourethroplasty | Reconstruction — Graft-Based | 73–89% across techniques | Short posterior stenoses where a fully endoscopic graft or mucosal-realignment approach is preferred over open or robotic reconstruction. |
| Permanent Suprapubic Catheter | Salvage / Diversion | Temporizing or definitive | Devastated posterior urethra in non-reconstruction candidates; bridge or definitive drainage. |
| Continent Catheterizable Channel (Mitrofanoff) | Salvage / Diversion | Salvage / definitive | Continent abdominal-stoma alternative to permanent SPT after failed VUAS reconstruction. |
| Urinary Diversion ± Cystectomy | Salvage / Diversion | Last resort | Last resort for failed reconstruction in radiated, fibrotic, or comorbid patients with refractory VUAS. |